ClinicalTrials.gg
Active, not recruitingNCT06908876Updated May 27, 2026

A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME)

A Phase 2 interventional study of IBI302 and IBI302 in Diabetic Macular Oedema, sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center). Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center) (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.

02

Conditions studied

  • Diabetic Macular Oedema
03

In context

Lead sponsor

Innovent Biologics Technology Limited (Shanghai R&D Center) is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Form (ICF) must be signed before participating in the study, compliance is good, and willing to complete the visit as planned;
  • Subjects aged 18-80 years (inclusive) at the time of screening, and diagnosed with type I or type II diabetes;
  • DME involved the macular fovea at screening;
  • CST≥320 μm as confirmed by OCT in the study eye at screening.
  • At baseline, visual acuity loss in the study eye due to DME with BCVA ranging from 19 to 78 ETDRS letters (inclusive);
  • Currently use of insulin, or other injectable drugs, or oral hypoglycemic agents to treat diabetes, ≤10% at screening;

Exclusion criteria

Exclusion criteria: Eye disease

  • High-risk PDR in the study eye;
  • Dense hard exudation that destroyed the fovea structure of the macula in the study eye;
  • Iris neovascularization in the study eye;
  • Other systemic/ocular disease associated with the study eye may cause subjects fail to respond to study treatment or confuse the interpretation of study findings;
  • Uncontrolled glaucoma in the study eye; Eye treatment
  • Any previous treatment with IBI302 in the study eye before baseline;
  • Intravitreal injection of anti-VEGF or anti-complement agents in the study eye within 90 days prior to baseline;
  • Panretinal photocoagulation or macular laser (focal, grid or micropulse) in the study eye within 90 days prior to baseline;
  • Cataract surgery was performed in the study eye within 90 days prior to baseline;
  • YAG laser capsulotomy or YAG laser peripheral iridotomy were performed in the study eye within 90 days prior to baseline.
  • Any other intraocular surgery (eg, corneal transplantation, glaucoma filtration, pars plana vitrectomy, or radiotherapy) Systemic diseases/treatments
  • Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable antidiabetic medication \<90 days prior to administration.
  • Uncontrolled hypertension.
  • Systemic use of anti-VEGF or anti-complement agents within 90 days prior to baseline
  • The presence of any other pre-existing disease, metabolic disorder, abnormal results on a physical examination or clinical laboratory examination that may reasonably be suspected of causing with the drug, or affecting the interpretation of study results, or placing subjects at high risk of treatment complications (e.g., coagulation dysfunction, history of acute cardiovascular and cerebrovascular disease, history of treated or untreated within the past 5 years, etc.);
  • Systemic treatment for suspected or active systemic infection (e.g., tuberculosis, , , etc.);
  • Pregnant or lactating women.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    IBI302 Dose 8mg

    Drug: IBI302 8mg/eye; Intraocularinjection

    Biological: IBI302

  • Active comparator
    Faricimab

    Drug: Faricimab 6mg/eye; Intraocularinjection

    Drug: Faricimab

  • Experimental
    IBI302 Dose 4mg

    Drug: IBI302 4mg/eye; Intraocularinjection

    Biological: IBI302

Interventions

  • BiologicalIBI302

    4 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by Pro re nata (PRN) regimen.

  • BiologicalIBI302

    8 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by PRN regimen.

  • 6 mg faricimab will be administered by intravitreal injection into the study eye once every 4 weeks for 4 consecutive months, followed by PRN regimen.

06

What researchers measure

Primary outcomes

  1. BCVA change from baseline

    Change from baseline in BCVA as measured on The BCVA is measured by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at week 16.

    Time frame: From Baseline through At Week 16

Secondary outcomes

  1. The proportion of patients with an ≥ 2-step DRSS improvement

    DRSS level is evaluated by color fundus photography (CFP).

    Time frame: At Week 16 and 36

  2. The proportion of patients with PDR

    The presence of PDR is evaluated by CFP.

    Time frame: The proportion of patients with PDR

  3. The proportion of new developed PDR

    The presence of new developed PDR is evaluated by CFP.

    Time frame: At Week 16 and 36

  4. Change from baseline in BCVA over time

    Change from baseline in BCVA as measured on ETDRS chart

    Time frame: From Baseline through Week 36

  5. The proportion of patients with CST < 320 μm over time

    CST is measured by Optical coherence tomography (OCT).

    Time frame: From Baseline through Week 36

  6. AEs over time

    All AEs were recorded and the investigator made an assessment on severity and causality of each AE.

    Time frame: From Baseline through Week 36

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 3, 2025
StartActual
Apr 24, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 28, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06908876
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Apr 24, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
May 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI302

Start the discussion